This article is more than 5 years old. Information may no longer be current.

PCORI opens comment period on peer review, release of research findings draft

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The Patient-Centered Outcomes Research Institute approved its draft proposal process for peer review and public release of primary research findings and has opened a public comment period that will close on Friday, Nov. 7.

“Our proposed peer review process and open science framework aim to advance the transparency and quality of useful new evidence,” Joe Selby, MD, MPH, PCORI executive director, said in a press release. “We expect to benefit greatly from input during the public comment period for the draft peer review proposal and we look forward to issuing the final process.”

A public forum will be held on Sept. 29 at the National Press Club in Washington, D.C., from 8:30 a.m. to 11 a.m. EDT. Registration is open until 5 p.m. EDT, Sept. 24. A free webcast also will be available, with details made available before the event.

PCORI said comments will be analyzed and revisions will be made to the draft proposal as necessary. A final proposal is expected to be presented to the PCORI board for consideration for adoption in February or March.

PCORI was established as a result of legislation in the Affordable Care Act. It was authorized by Congress in 2010 to fund research designed to give patients, caregivers and clinicians evidence-based information, as well as to fund comparative clinical effectiveness research, the release said.